Tom Burris, Ph.D., FAAAS, FAHA, recently received grant funds totaling more than $740,000 from Mallinckrodt Pharmaceuticals.
The funding will support Burris’s research in the Center to develop drugs targeting muscle function. Specifically, the research will focus on the creation of therapeutics to treat Duchenne muscular dystrophy and muscle loss caused by aging, known as sarcopenia.